Biotech Values

[DewDiligence]

PDS Biotechnology reverse-merges into EDGE:

https://finance.yahoo.com/news/edge-therapeutics-enters-merger-agreement-113000261.html

PDS Biotechnology is developing PDS0101 for the treatment of multiple human papilloma virus (HPV)-induced cancers, including cervical, anal and head and neck cancers. PDS Biotechnology plans to initiate multiple Phase 2/3 clinical trials for PDS0101 in HPV-associated cancers.

…immediately following the merger, the former PDS security holders will own approximately 70% of the combined company and existing Edge security holders will own approximately 30% of the combined company…

…the combined company’s common stock is expected to continue to trade on NASDAQ under a new ticker symbol to be announced at a later date…

Slides from today’s CC:
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDEzOTc3fENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636788330644623176